Blueprint Medicines Corporation (BPMC)
|52 Week Range||37.82-79.4|
|1y Target Est||-|
|DCF Unlevered||BPMC DCF ->|
|DCF Levered||BPMC LDCF ->|
|Debt / Equity||162.28%||Buy|
Upgrades & Downgrades
Latest BPMC news
Blueprint's (BPMC) Q4 Earnings & Sales Top Estimates, Stock Up
17 February 2023
Blueprint Medicines (BPMC) announces better-than-expected financial performance in fourth-quarter and full-year 2022. Stock up in the aftermarket hours, following the news release.
Blueprint Medicines Corporation (BPMC) Q4 2022 Earnings Call Transcript
16 February 2023
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Havi...
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
16 February 2023
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.93% and 18.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Blueprint's (BPMC) Cancer Study Put on Partial Hold by FDA
13 February 2023
Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA.
Blueprint Medicines: A Slow But Steady Blueprint For Success
14 December 2022
Blueprint Medicines Corporation has multiple approved drugs and potential label expansions. Sales have not been as good as expected.
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM
23 November 2022
Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.
Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark
2 November 2022
Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.
Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?
5 October 2022
Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to generate incremental sales and combat stiff competition.
Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal
15 September 2022
Blueprint has a few recently approved therapies, and has recently sold royalties for over $1 billion. While this limits revenue potential now, the profits can be leveraged back into advancing the pipe...
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >